Meta-analysis of Ki-67 Expression for Recurrence in Patients with Solid Pseudopapillary Tumor of the Pancreas.

Caifeng Zou,Feng Yang,Deliang Fu

DOI: https://doi.org/10.1016/j.hpb.2019.09.018

IF: 3.842

2020-01-01

HPB

Abstract:Meta-analysis of Ki-67 expression for recurrence in patients with solid pseudopapillary tumor of the pancreasWe read with great interest the comprehensive systematic review and meta-analysis by Yepuri and colleagues, 1 which investigated predictors of recurrence in patients with solid pseudopapillary tumor of the pancreas (SPTP).We admire the authors for their efforts on such an excellent review, but have some concerns about their result that Ki-67 4% was not associated with a significant odds ratio for recurrence.We would like to replicate the result of this meta-analysis on the predictive value of Ki-67 4%.Review of the literature was performed by searching PubMed, Scopus, and Web of Science databases between September 2002 and September 2017 with the same search terms listed by the authors and Ki-67.A total of 239 citations, with some duplicates among databases, were identified.3][4][5] Our meta-analysis showed that Ki-67 4% was associated with significant odds for recurrence (OR 43.56, 95% confidence interval 4.06-467.81,p = 0.002, Fig. 1).The heterogeneity within the studies was not significant (Heterogeneity Chi 2 4.51, p = 0.21).Although our results are encouraging for Ki-67 as a predictor of recurrence in patients with SPTP, prospective studies including a large number of patients are needed for validation.Overall, due to the changes we presented here, the result regarding Ki-67 of the Yepuri et al. study should be interpreted with caution.Figure 1 The forest plot of the risk of recurrence in patients with SPTP who had Ki-67 4%